| Identification | Back Directory | [Name]
sodium:(5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidin-3-ide-2,4-dione:hydrate | [CAS]
1356195-42-0 | [Synonyms]
sodium:(5Z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidin-3-ide-2,4-dione:hydrate | [Molecular Formula]
C18H12N3NaO3S | [MOL File]
1356195-42-0.mol | [Molecular Weight]
373.361 |
| Hazard Information | Back Directory | [Uses]
GSK 1059615 is a potent inhibitor of PI 3-kinase α (PI3Kα). GSK 1059615 inhibits proliferation in BT474 cells and attenuates MAPK signaling. | [Biological Activity]
GSK 1059615 is a phosphatidylinositol-3-kinases (PI3K) inhibitor. GSK 1059615 inhibits proliferation of breast cancer BT474 cells via four different mechanisms th at include retinoblastoma 1 (RB1)-mediated cell cycle arrestelevated forkhead box protein O1 (FOXO) signalingdeduced MYC and transferrin receptor (TFRC) signaling and decreased cellular metabolism. AdditionallyGSK 1059615 can suppress cell proliferation by decreasing mitogen-activated protein kinase (MAPK) signaling and imparts sensitivity to phosphoinositide 3-kinase (PI3K) inhibitor in cells resistant to the protein kinase B or AKT inhibitor. GSK 1059615 functions as a druggable target to reduce radiation-induced apoptosis in NCCIT cells. GSK 1059615 has entered clinical trial in patients with solid tumors or lymphoma and refractory malignancies.''GSK 1059615 is a poten |
|
|